Company intelligence / Profile preview
Philikos BV
Nijmegen, Gelderland, Netherlandsphilikos.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Philikos is developing T‑Guard, a combination of two toxin-conjugated antibodies designed to transiently deplete overactive T and NK cells in patients with systemic sclerosis. This approach aims to reset the immune system more safely than autologous stem cell transplantation. The drug is entering clinical evaluation, with recent funding secured for patient studies. No published clinical results yet.
- Therapeutic areas
- RheumatologyImmunology
- Modalities
- Toxin-conjugated antibodiesBiologics (antibody-based therapy)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Radboud university medical center (Radboudumc)Health Holland (grant provider)Biotech Booster (grant provider)Oost NL and Essential Investments provided convertible loans/funding support
Beyond the preview
Go deeper on Philikos BV.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Philikos BV.